Trial Profile
A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary) ; Corticotropin (Primary) ; Methylprednisolone; Prednisone
- Indications Optic neuritis
- Focus Therapeutic Use
- 24 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 29 Sep 2021 Planned End Date changed from 1 May 2021 to 1 Dec 2021.
- 29 Sep 2021 Planned primary completion date changed from 1 May 2021 to 1 Dec 2021.